AGENDA AT A GLANCE
8:30
Registration & Coffee
Unlocking Commercial Success in DACH’s Cell & Gene Therapy
10:40
Networking Break
Decentralised Production for Next-Gen Cell & Gene Therapies
11:15
Manufacturing Practices in AAV Gene Therapy Manufacturing - Current Challenges and Future Solution
- Key manufacturing challenges in AAV gene therapy, from upstream to fill–finish
- Ensuring consistency, quality, and scalability across clinical and commercial stages
- Emerging technologies and process innovations shaping future AAV production
12:05
12:30
Lunch Break
Overcoming Bottlenecks in Viral Vector Manufacturing
13:30
Optimising & Automating Viral Vector’s Personalised Vaccines PreGMP Steps : Reducing Complexity & Driving Scale
- Streamlining pre-GMP workflows for viral vector–based personalised vaccines
- Automation strategies to reduce complexity and manual intervention
- Building scalable foundations for downstream GMP manufacturing
14:20
Optimising & Automating Viral Vector’s Personalised Vaccines GMP Production : Lowering Costs & Driving Scale
- Optimising GMP manufacturing workflows for viral vector–based personalized vaccines
- Automation strategies to reduce costs and improve process consistency
- Enabling scalable, compliant production for broader patient access
15:35
Networking Break
Poster Exhibition:
Accelerating Next Generation Cell Therapy Manufacturing with Scalable Immune Cell Engineering Workflows
17:00
Key Takeaways
17:15
Drink Reception & End of Day 1
Quality Assurance & Process Intensification
9:10
Process Intensification and Lifecycle Management Strategy of Biopharmaceuticals Post Launch
- Applying process intensification to enhance efficiency and robustness post-launch
- Managing lifecycle changes while maintaining regulatory compliance
- Driving continuous improvement across commercial biopharmaceutical manufacturing
9:35
Process Intensification Opportunities, Challenges and Solutions: Product Quality, Harvest and Scale up Considerations for Intensified Processes
- Key opportunities and challenges in implementing intensified bioprocesses
- Impact on product quality, harvest strategies, and process control
- Practical considerations for scale-up and operational robustness
10:00
Networking Break
Single-Use & Facility Strategies
10:30
11:20
Intensification by Design: Integrated Continuous Biomanufacturing for Viral Vector Processes
- Designing integrated continuous platforms for viral vector manufacturing
- Benefits of intensification across productivity, consistency, and facility footprint
- Technical and regulatory considerations for continuous viral vector processes
11:45
Lunch Break
Manufacturing Innovations for Allogeneic and In Vivo Therapies
13:00
CARKey™ – A multi-specific, dual receptor CAR T platform to overcome solid tumour antigen heterogeneity
- Addressing solid tumour antigen heterogeneity through multi-specific CAR T design
- Dual-receptor architecture to enhance targeting and therapeutic efficacy
- Platform potential for broader applicability across solid tumour indications
13:50
Networking Break
Smart Factories: The Role of Digitalisation & AI
Supply Chain & Logistics
16:30
Chairman’s Closing Rearks
16:30
END OF CONFERENCE
